Edition:
United Kingdom

Dova Pharmaceuticals Inc (DOVA.OQ)

DOVA.OQ on NASDAQ Stock Exchange Global Market

31.30USD
7:13pm GMT
Change (% chg)

$-0.33 (-1.04%)
Prev Close
$31.63
Open
$31.50
Day's High
$32.55
Day's Low
$31.14
Volume
20,731
Avg. Vol
36,885
52-wk High
$32.55
52-wk Low
$16.98

Summary

Name Age Since Current Position

Paul Manning

61 2017 Chairman of the Board

Alex Sapir

50 2017 President, Chief Executive Officer, Director

Douglas Blankenship

55 2017 Chief Financial Officer

Kevin Laliberte

39 2017 Senior Vice President - Product Development

Lee Allen

65 2017 Chief Medical Officer

Sean Stalfort

47 2016 Director

Steven Goldman

65 2017 Independent Director

Roger Jeffs

55 2017 Independent Director

Alfred Novak

69 2017 Independent Director

Biographies

Name Description

Paul Manning

Mr. Paul B. Manning is Chairman of the Board of the company. He has served as the Chairman of our board of directors since June 2017 and as a member of our board of directors since September 2016. Mr. Manning is the President and Chief Executive Officer of PBM Capital Group, LLC, a private equity investment firm in the business of investing in healthcare and life-science related companies, which he founded in 2010. Prior to that, Mr. Manning founded PBM Products in 1997, a producer of infant formula and baby food, which was sold to Perrigo Corporation in 2010. Mr. Manning is a director of various private companies and AveXis, Inc., a publicly traded clinical-stage gene therapy company, and was previously on the board of directors of Perrigo Corporation and Concordia Healthcare Corp. Mr. Manning received a B.S. in microbiology from the University of Massachusetts. Our board of directors believes that Mr. Manning should serve as a director based upon on his over 30 years of managerial and operational experience in the healthcare industry and as an investor in healthcare related companies.

Alex Sapir

Mr. Alex Sapir is President, Chief Executive Officer, Director of the company since January 2017. From January 2006 to May 2016, Mr. Sapir served as Executive Vice President, Marketing and Sales for United Therapeutics Corporation, a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. Prior to his time at United Therapeutics Corporation, from January 2003 to January 2005 Mr. Sapir served as Senior Director, Marketing for Guilford Pharmaceuticals. He began his career at GlaxoSmithKline serving in various commercial roles in the United States and Europe. Mr. Sapir is a routine guest lecturer on the topic of pharmaceutical marketing strategy at Duke University's Fuqua School of Business. Mr. Sapir holds a B.A. in Economics from Franklin and Marshall College and an M.B.A. from Harvard Business School.

Douglas Blankenship

Mr. Douglas L. Blankenship is Chief Financial Officer of the company since March 2017. From November 2015 to February 2017, Mr. Blankenship took a sabbatical to focus on family and relocated to the Research Triangle, North Carolina. From October 2008 to October 2015, Mr. Blankenship served as Director, Finance—Global Quality & Compliance and Technical Regulatory, of Genentech and Roche Pharmaceuticals, a biotechnology company focused on discovering, developing, manufacturing and commercializing medicines to treat patients with serious or life-threatening medical conditions. Prior to his time at Genentech, from June 2006 to January 2008, Mr. Blankenship served as Finance Director for Amgen Technology Ireland. Mr. Blankenship holds a B.S. in Accounting from California Polytechnic State University, San Luis Obispo and an M.B.A. from The Wharton School, University of Pennsylvania.

Kevin Laliberte

Dr. Kevin Laliberte is Senior Vice President - Product Development of the company since March 2017. From 2003 to March 2017, Dr. Laliberte held various positions at United Therapeutics Corporation, including as the Senior Vice President, Product Development and Clinical Operations from March 2015 to March 2017, as the Associate Vice President Product Development from March 2013 to February 2015 and as the Senior Director Product Development from 2010 to March 2013. Dr. Laliberte holds a Pharm.D. from the University of Michigan and completed a Drug Development and Clinical Research Fellowship at the University of North Carolina School of Pharmacy and GlaxoSmithKline.

Lee Allen

Dr. Lee F. Allen, M.D., Ph.D. is Chief Medical Officer of the company since April 2017. From January 2016 to April 2017, Dr. Allen served as Chief Medical Officer managing Clinical Development, Medical Affairs and Regulatory Affairs at Argos Therapeutics. Dr. Allen served as Chief Medical Officer at Spectrum Pharmaceuticals from March 2013 to January 2016. From August 2007 to March 2013, Dr. Allen served as Chief Medical Officer at AMAG Pharmaceuticals. From 2003 through 2007, Dr. Allen served as the Clinical Site Head and Global Oncology Therapeutic Area Director for Wyeth Pharmaceuticals' research and development site in Cambridge, MA. From 1999 to 2003, Dr. Allen helped establish Oncology as a new therapeutic area at Pfizer and served as Executive Director and Site Therapeutic Area Leader for the Ann Arbor Oncology portfolio. Dr. Allen holds a Ph.D. and M.D. from the Rutgers Biomedical and Health Sciences (formerly the University of Medicine and Dentistry of New Jersey), and completed Residency training in Internal Medicine and Fellowship training in Hematology and Oncology at the Duke University Medical Center. As a postdoc, Dr. Allen investigated signal transduction pathways at Duke in the Howard Hughes Laboratory of Nobel Laureate, Dr. Robert Lefkowitz, and has authored or co-authored more than 50 publications.

Sean Stalfort

Mr. Sean Stalfort is Director of the company since September 2016. He has been a partner at PBM Capital Group, LLC, a private equity investment firm in the business of investing in healthcare and life-science related companies, since May 2010. Prior to joining PBM Capital Group, LLC, Mr. Stalfort was the Executive Vice President for New Business Development/M&A for PBM Products. Mr. Stalfort is also a founding Partner of Octagon Partners and Octagon Finance, historic tax credit real estate companies. Mr. Stalfort is a director of several private healthcare companies. Mr. Stalfort also served as our President from April 2016 until December 2016. Mr. Stalfort received a B.A. in Business Economics and Political Science from Brown University.

Steven Goldman

Mr. Steven M. Goldman is Independent Director of the company since May 2017. He has been a Partner of Kramer Levin Naftalis & Frankel LLP since 2009. Mr. Goldman specializes in mergers and acquisitions, financings, joint ventures, private placements, leveraged buyouts and general corporate counseling. He has represented numerous banks in connection with financing of acquisitions and recapitalizations, and insurance brokerages in connection with regulatory enforcement issues and in purchase and sale transactions. From 2006 to 2009, before joining Kramer Levin, Mr. Goldman was the State of New Jersey's Department of Banking and Insurance Commissioner, appointed by Governor Jon S. Corzine. In that role, Mr. Goldman chaired the Reinsurance Task Force at the National Association of Insurance Commissioners which completed a framework for modernizing the regulation of reinsurance in the United States and between the United States and other countries. Mr. Goldman has served as a director of Bank Leumi USA since May 2015. Mr. Goldman also served as a Director of ConnectOne Bank and ConnectOne Bancorp, Inc from 2011 to February 2014. He also Chaired the International Insurance Relations Committee of the NAIC, and the Reinsurance and other Forms of Risk Transfer Subcommittee on behalf of the United States at the International Association of Insurance Supervisors from 2007 to 2009. Mr. Goldman has testified before Congress on multiple occasions regarding insurance regulation and health care reform. Mr. Goldman is on the Dean's Board of Advisors for The George Washington University Law School, is a Member of the Bar in New York and New Jersey and is currently the Chair of the Operations and Finance Committee, a member of the Executive Committee, and Assistant Treasurer of the New Jersey Performing Arts Center and a member of the Board of Managers of Theatre Square Development Company.

Roger Jeffs

Dr. Roger A. Jeffs is Independent Director of the company since May 2017. He has served as a Senior Advisor of United Therapeutics Corporation since June 2016. Dr. Jeffs served as the Co-Chief Executive Officer of United Therapeutics Corporation from January 2015 to June 2016 and President of United Therapeutics Corporation from April 2001 to June 2016. Dr. Jeffs joined United Therapeutics Corporation in September 1998 as Director of Research, Development and Medical and also served as its Chief Operating Officer from April 2001 to December 2014. Prior to 1998, Dr. Jeffs worked at Amgen, Inc. as Manager of Clinical Affairs and Associate Director of Clinical Research from 1995 to 1998. Dr. Jeffs served as a Director of United Therapeutics Corporation from 2002 until June 2016. Dr. Jeffs has been a Director of Axsome Therapeutics, Inc. since December 2014 and serves as its Lead Director. Dr. Jeffs holds a B.S. in Chemistry from Duke University and Ph.D. in Pharmacology from the University of North Carolina.

Alfred Novak

Mr. Alfred J. Novak is Independent Director of the company since May 2017. He has served on the board of LivaNova, a global medical device company since October 2015. From 2007 until October 2015, Mr. Novak served on the board of Cyberonics, until its merger with Sorin S.p.a. to form LivaNova. From April 2014 until March 2015, Mr. Novak served as President and Chief Executive Officer of Syntheon Cardiology, LLC, an early-stage company developing a percutaneous prosthetic aortic heart valve. From September 1999 until January 2014, he served on the board of directors of OrbusNeich Medical Technology Company, Ltd., a privately held interventional cardiology company, where he was Chairman and Chief Executive Officer from 2010 until October 2013. He previously served as Chairman of the board of directors of ProRhythm, Inc., a privately held company dedicated to the treatment of atrial fibrillation through the use of ultrasound technologies. In 1998, he was a founder of Syntheon, LLC, a privately held company that focused on minimally invasive medical devices for the gastroenterology and vascular markets. From 2002 until 2006, Mr. Novak was the President, Chief Executive Officer and a director of Novoste Corporation, a publicly held interventional cardiology company. From 1998 until 2002, Mr. Novak was a member of the board of directors of Sutura, Inc., a vascular closure company. Mr. Novak was President, Chief Executive Officer and a director of Biosense, Inc., an electrophysiology company, from 1996 until 1998, when it was acquired by Johnson & Johnson. He was employed by Cordis Corporation, then a publicly held cardiology company, from 1984 until 1996, when it was acquired by Johnson & Johnson. Mr. Novak currently serves on the board of directors of Restoring Heroes Foundation, an organization devoted to assisting veterans with obtaining access to new and progressive therapies. Formerly, he was on the board of Goodwill Industries of South Florida. Mr. Novak received an M.B.A. from the Wharton School.